Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield ND Prior Auth Drug List | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - North DakotaPolicy N/A

    Medicaid Expansion Restricted Use Drug Precertification List

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Dakota policy alerts

    Know when Blue Cross Blue Shield - North Dakota releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    List of prescription medications and medical-benefit drugs subject to precertification (prior authorization) and limited dispensing for Medicaid Expansion members; affects providers submitting medical or pharmacy benefit claims in North Dakota.

    Policy Summary
    PayerBlue Cross Blue Shield - North Dakota
    PolicyMedicaid Expansion Restricted Use Drug Precertification List
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit and obtain precertification (prior authorization) using the correct medical prior authorization form and appropriate HCPCS/J/Q codes for listed drugs and supplies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100+listed drugs and biologics requiring precertification (partial list in this excerpt)
    ~120+HCPCS/J/Q coded items
    A9276-A9278CGM device codes noted
    1-833-777-5779Member Services
    Updated 1/1/2022Document update shown in excerpt

    Coverage Criteria

    Precertification requirement

    Covered when ALL of the following are met

    Precertification requirement: A precertification (prior authorization) request is submitted and approved for the listed restricted use drug (brand or generic equivalent).

    Providers must use the medical drug prior authorization form for medical-benefit drugs (see provided link) and consult the Preferred Drug List (PDL) to determine pharmacy vs medical benefit processing.

    Medications that are administered by the patient or another non‑professional and do not require professional administration are considered self‑administered and are not typically covered under the medical benefit. These items are generally processed through the pharmacy benefit per the Medical Policy: Medications and Diabetic Supplies Payable on the Pharmacy Benefit. Examples in this policy include continuous glucose monitor components (e.g., A9276 sensor, A9277 transmitter, A9278 receiver) and other codes noted as processed at pharmacy point‑of‑sale.

    The lists of HCPCS/J/K/Q/S codes shown elsewhere in this document are a coding reference only and do not by themselves define clinical coverage or exclusions. Providers must use the applicable policy sections and medical necessity rules to determine coverage, and must submit prior authorization requests and claims using the correct HCPCS/J/K/Q/S codes shown in the coding tables.

    Policy Summary
    PayerBlue Cross Blue Shield - North Dakota
    PolicyMedicaid Expansion Restricted Use Drug Precertification List
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit and obtain precertification (prior authorization) using the correct medical prior authorization form and appropriate HCPCS/J/Q codes for listed drugs and supplies.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Billing CodesProvider Actions and RequirementsSite of Care / Benefit ProcessingDefinitionsBackground

    Coding and Billing Codes

    Precertification drug HCPCS/J/Q codesHCPCSCovered
    Q2055ABECMA (idecabtagene vicleucel)
    J0791ADAKVEO (crizanlizumab-tmca)
    J9042ADCETRIS (brentuximab)
    J0172ADUHELM (aducanumab-avwa)
    J1931ALDURAZYME (laronidase)
    J0256ARALAST NP / PROLASTIN-C / ZEMAIRA (alpha1-proteinase inhibitor)
    J9302ARZERRA (ofatumumab)
    J1554ASCENIV (immune globulin - IV)
    J9118ASPARLAS (calaspargase pegol-mknl)
    J9035AVASTIN (bevacizumab) / C9257 (oncology diagnosis only)
    1–10 of 156
    1/16
    Additional HCPCS/J and A codes and examples notedHCPCS
    A9276Sensor; invasive, disposable, for use with interstitial CGM system, one unit = 1 day supply
    A9277Transmitter; external, for use with interstitial CGM system
    A9278Receiver (monitor); external, for use with interstitial CGM system
    J0135Injection, adalimumab, 20 mg (Humira)
    J0364Injection, apomorphine hydrochloride (Apokyn)
    J0593Injection, lanadelumab-flyo, 1 mg (Takhzyro)
    J0596Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units
    J0597Injection, C-1 esterase inhibitor (human), Berinert, 10 units
    J0598Injection, C-1 esterase inhibitor (human), Cinryze, 10 units
    J0599Injection, C-1 esterase inhibitor (human), Haegarda, 10 units
    1–10 of 34
    1/4
    Listed J-codes (part 1)HCPCS
    J0597Injection, C-1 esterase inhibitor (human), Berinert, 10 units.
    J0598Injection, C-1 esterase inhibitor (human), Cinryze, 10 units.
    J0599Injection, c-1 esterase inhibitor (human), (Haegarda), 10 units.
    J0717Injection, certolizumab pegol, 1 mg (Cimzia).
    J1000Injection, depo-estradiol cypionate, up to 5 mg.
    J1071Injection, testosterone cypionate, 1 mg.
    J1110Injection, dihydroergotamine mesylate, per 1 mg (D.H.E. 45).
    J1290Injection, ecallantide, 1 mg (Kalbitor).
    J1438Injection, etanercept, 25 mg (Enbrel).
    J1595Injection, glatiramer acetate, 20 mg (Copaxone).
    1–10 of 18
    1/2
    Listed J-codes (part 2)HCPCS
    J2212Injection, methylnaltrexone, 0.1 mg (Relistor).
    J2793Injection, rilonacept, 1 mg (Arcalyst).
    J2941Injection, somatropin, 1 mg (Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, Saizen, Serostim, Zorbtive).
    J3110Injection, teriparatide, 10 mcg (Forteo).
    J3121Injection, testosterone enanthate, 1 mg.
    J3145Injection, testosterone undecanoate, 1 mg (Aveed).
    J3262Injection, tocilizumab, 1 mg (Actemra).
    J3357Ustekinumab, for subcutaneous injection, 1 mg (Stelara).
    J3535Drug administered through a metered dose inhaler.
    J7170Injection, emicizumab-kxwh, 0.5 mg (Hemlibra).
    Hemostasis factor J-codesHCPCS
    J7175Injection, factor x, (human), 1 i.u. (Coagadex).
    J7179Injection, von Willebrand factor (recombinant), (Vonvendi), 1 i.u. vwf:rco.
    J7180Injection, factor XIII (antihemophilic factor, human), 1 i.u. (Corifact).
    J7181Injection, factor XIII a-subunit, (recombinant), per IU (Tretten).
    J7182Injection, factor VIII, (antihemophilic factor, recombinant), (Novoeight), per IU.
    J7183Injection, von Willebrand factor complex (human), Wilate, 1 IU VWF:RCo.
    J7185Injection, factor VIII (Antihemophilic factor, recombinant) (XYNTHA) per IU (Xyntha).
    J7186Injection, antihemophilic factor VIII/von Willebrand factor complex (human), per factor VIII IU (Alphanate).
    J7187Injection, von Willebrand factor complex (Humate-P), per IU VWF:RCo.
    J7188Injection, factor VIII (antihemophilic factor, recombinant), (OBIZUR), per i.u.
    1–10 of 12
    1/2
    Additional hemostasis and other J-codesHCPCS
    J7192Factor VIII (antihemophilic factor, recombinant) per IU, not otherwise specified (Kogenate FS, Advate, Recombinate).
    J7193Factor IX (antihemophilic factor, purified, non-recombinant) per IU (Alphanine SD, Mononine).
    J7194Factor IX, complex, per IU (Profilnine).
    J7195Injection, factor IX (antihemophilic factor, recombinant) per IU (Benefix, Ixinity).
    J7198Anti-inhibitor, per IU (Feiba NF).
    J7200Injection, factor IX, (antihemophilic factor, recombinant), Rixubis, per IU (Rixubis).
    J7201Injection, factor ix, fc fusion protein, (recombinant), alprolix, 1 i.u. (Alprolix).
    J7202Injection, factor ix, albumin fusion protein, (recombinant), idelvion, 1 i.u. (Idelvion).
    J7203Injection, factor ix, (antihemophilic factor, recombinant) glycopegylated, (Rebinyn), 1 iu.
    J7204Injection, factor viii, antihemophilic factor (recombinant), (Esperoct), glycopegylated-exei, per iu.
    1–10 of 19
    1/2
    K/Q/S codes and device suppliesHCPCS
    J7686Treprostinil, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form 1.74 mg (Tyvaso).
    K0553Supply allowance for therapeutic continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply = 1 unit of service.
    K0554Receiver (monitor), dedicated, for use with therapeutic glucose continuous monitor system.
    Q3027Injection, interferon beta-1a, 1 mcg for intramuscular use (Avonex).
    Q3028Injection, interferon beta-1a, 1 mcg for subcutaneous use (Rebif).
    Q4074Iloprost, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, up to 20 micrograms (Ventavis).
    S0090Sildenafil citrate, 25 mg (Viagra).
    S0117Tretinoin, topical 5 grams (Retin-A, Renova).
    S0138Finasteride, 5 mg (Propecia, Proscar).
    S1030Continuous noninvasive glucose monitoring device, purchase (for physician interpretation of date, use CPT code).
    1–10 of 15
    1/2
    Smoking cessation S-codesHCPCS
    S4990Nicotine patches, legend.
    S4991Nicotine patches, non-legend.
    S4995Smoking cessation gum.
    CGM sensor daily supply — one unit = 1 day supply
    DefinitionA9276 sensor is billed as one unit = 1 day supply for continuous glucose monitoring (CGM) sensors.
    Related device codesA9277 = transmitter (external) and A9278 = receiver (monitor) for interstitial CGM systems.
    Benefit processingThese CGM device codes are processed through pharmacy point-of-sale systems per Department of Human Services guidance.
    Site-of-care noteMedications and supplies administered by an individual (self-administered) are typically processed on the pharmacy benefit, not the medical benefit.

    Provider Actions and Requirements

    Prior Authorization

    Precertification / Prior Authorization required

    Prior authorization (Precertification) is required for the listed restricted use drugs (both brand and generic equivalents) and for medical-benefit drugs administered using the specified HCPCS/J/Q codes; submit a precertification request and obtain approval before dispensing or administering these drugs when processed under the medical benefit.

    • Both brand name drugs and generic equivalents require Precertification (Prior Approval).
    • A precertification (prior authorization) request must be submitted and approved for the listed restricted use drug.
    Billing Rule

    Precertification requires correct HCPCS code use

    When requesting precertification or submitting claims, providers must use the appropriate HCPCS, J-, Q-, K-, and S- codes listed in this policy for the drug or supply being requested or billed.

    • The policy lists HCPCS/J/Q codes (e.g., J0597, J7170, J3357, Q2055) and device/supply codes (e.g., A9276–A9278, K0553) that must be used for prior authorization and claims.
    • Codes that identify pharmacy-processed items (A9276–A9278, J0135 examples) are included to determine processing benefit.
    Prior Authorization

    Submit prior authorization with the appropriate HCPCS code

    Submit prior authorization using the appropriate HCPCS code for the listed drug or supply when requesting precertification; the policy explicitly lists codes to be used for prior authorization and claim submission.

    • The policy states prior authorization is required for drugs using specified HCPCS/J/Q codes and provides a comprehensive code list.
    • Both brand and generic equivalents are subject to the same precertification requirements and coding expectations.
    Note

    Use pharmacy point-of-sale processing for self‑administered supplies when applicable

    When drugs or devices are processed through pharmacy point of sale (e.g., CGM supplies A9276–A9278 or other listed items), consult the PDL and use pharmacy billing processes rather than medical-benefit precertification forms.

    • A9276–A9278 and other codes are processed through pharmacy point-of-sale systems according to the Department of Human Services.
    • Consult the Preferred Drug List to confirm processing benefit and any additional prior authorization requirements.
    Documentation Required

    Use medical prior authorization form and consult PDL

    Providers must use the medical drug prior authorization (Precertification) form for drugs processed under the medical benefit; the fillable form is available at the URL provided in the policy.

    • Medical drug prior authorization forms: https://www.bcbsnd.com/content/dam/bcbsnd/documents/forms/providers/precertification/outpatient-fillable.pdf
    • Consult the Preferred Drug List (PDL) to determine whether a medication is processed through the pharmacy benefit or requires medical-benefit precertification.
    Note

    Member services and grievance contacts

    Direct members to Member Services for language assistance, accessibility support, or to obtain grievance forms; providers may advise members to contact Member Services or the Civil Rights Coordinator for help filing grievances.

    • Member Services phone (toll-free): 1-833-777-5779 (TTY: 1-800-366-6888 or 711).
    • Grievance forms and filing instructions are available at www.medicaid.bcbsnd.com; Civil Rights Coordinator contact details are listed in the policy.
    Denial Risk

    Precertification required — risk of denial/non-payment

    Failure to obtain precertification (prior approval) for listed restricted-use drugs when required may result in denial of coverage or non-payment for the drug when it is subject to the medical benefit or limited dispensing.

    • Obtain and document prior authorization approval before administering or billing medical-benefit restricted drugs to avoid claim denials or non-payment.
    Denial Risk

    Coding-based denial risk — use listed HCPCS/J/K/Q/S codes

    Claims and precertification requests must include the specific HCPCS/J/K/Q/S code that corresponds to the drug or supply; omission or incorrect coding can cause precertification or claim processing issues and potential denials.

    • Use the exact HCPCS/J/Q/K/S code listed for the product (examples: J0597, J7170, A9276, K0553).
    • Codes for items that are pharmacy-processed (A9276–A9278, J0135 examples) determine benefit and processing pathway.

    Site of Care / Benefit Processing

    Note

    Determine site of care and billing based on benefit and administration

    Medications that do not require professional administration are considered self‑administered and are typically processed on the pharmacy benefit; determine site-of-care and billing path (office/infusion center vs pharmacy) based on benefit and administration.

    • Self‑administered items (e.g., CGM sensors/transmitters/receivers, certain injectable drugs when self-administered) are processed via pharmacy point-of-sale systems per the policy.
    • Medical‑benefit administration requires appropriate facility/provider coding (office or infusion center) and precertification when applicable.

    Definitions

    Restricted Use Drug - Precertification
    TermRestricted Use Drug - Precertification: A prescription medication or drug that may require Precertification (Prior Approval) and/or be subject to a limited dispensing amount.
    Applies toBoth brand-name drugs and generic equivalents require precertification when listed.
    ConsequenceFailure to obtain required precertification may result in denial of coverage or non-payment.
    Medical Drug
    DefinitionMedical Drug: A drug covered under the medical benefit that requires Precertification (Prior Approval).
    Prior authorization formProviders must use the medical drug prior authorization form available at the BCBSND outpatient fillable forms link.
    Processing noteMedical-benefit drugs require submission of precertification using appropriate HCPCS/J/Q codes as listed in the policy.
    Preferred Drug List (PDL)
    DefinitionPreferred Drug List (PDL): List of medications preferred and processed by pharmacy point-of-sale systems.
    UseConsult the most recent PDL to determine additional precertification/prior approval requirements and whether a medication or diabetic supply should be processed via pharmacy or medical benefit.
    Reference linkPDL available at the BCBSND preferred drug list web page (link provided in policy).

    Background

    This policy enumerates medications, biologics, and associated billing codes that require precertification (prior authorization) for Medicaid Expansion members in North Dakota. Both brand and generic equivalents listed require precertification when billed under the medical benefit or when the code is included on this restricted‑use list. Providers must submit and obtain an approved precertification before the drug or medical‑benefit administration to avoid potential denial of coverage or non‑payment.

    Precertification applies to medications billed with the HCPCS/J/Q/K/S codes listed in the coding sections (including specialty biologics, immune globulins, CAR‑T and gene therapies, hemostasis factors, inhalation products, device supplies and smoking cessation S‑codes). For items that do not require professional administration and are processed at point of sale (for example certain CGM components coded A9276, A9277, A9278), processing may occur via the pharmacy benefit and providers should consult the Preferred Drug List and the Medical Policy on pharmacy‑payable supplies to determine the appropriate benefit and submission process.